An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 μg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis

Cutis

Volumn 88, Issue 4, 2011, Pages 201-207

  Hudson, Charles P ^a   Kempers, Steven ^b   Menter, Alan ^c   Papp, Kim ^d   Smith, Stacy ^e   Sofen, Howard ^f   Colón, Luz E ^g   Johnson, Lori A ^g   Gottschalk, Ronald ^g  

^a Hudson Dermatology   (United States)

^b Minnesota Clinical Study Center   (United States)

^c BAYLOR RESEARCH INSTITUTE   (United States)

^d PROBITY MEDICAL RESEARCH   (Canada)

^e Dermatology and Consulting   (United States)

^f Dermatology Research Associates   (United States)

^g Galderma Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CLOBETASOL; GLUCOCORTICOID; VITAMIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PATHOLOGY; PATIENT SATISFACTION; PSORIASIS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; CALCITRIOL; CLOBETASOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PATIENT SATISFACTION; PSORIASIS; TREATMENT OUTCOME; VITAMINS; YOUNG ADULT;

EID: 84555203306     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-320.
2. Krueger G, Koo J, Kebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284.
3. van de Kerkhof P. Psoriasis. In: Bolognia JL, Jorizzo JL, Rapini RP, et al, eds. Dermatology. 1st ed. St. Louis, MO: Mosby; 2003:125-149.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. section 3. guidelines of care for the management and treatment of psoriasis with topical therapies [published online ahead of print February 13, 2009]. J Am Acad Dermatol. 2009;60:643-659.
5. Schoepe S, Schäcke H, May E, et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15:406-420.
6. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284.
7. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005;53(1, suppl 1):S17-S25.
8. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006;5:527-532.
9. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2007;6:428-435.
10. Lebwohl M, Ortonne JP, Andres P, et al. Calcitriol ointment 3 μg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis. 2009;83:205-212.
11. Austad J, Bjerke JR, Gjertsen BT, et al. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 1998;11:19-24.
12. Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol. 2006;55:637-641.
13. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology. 2006;213:319-326.
14. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotrieneointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39:447-450.
15. Toole JW. Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study. Skin Therapy Lett. 2007;12:1-3.
16. Lahfa M, Mrowietz U, Koenig M, et al. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol. 2003;13:261-265.
17. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006;78:348-354.
18. Beutner K, Chakrabarty A, Lemke S, et al. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006;5:357-360.
19. Sofen H, Hudson CP, Cook-Bolden FE, et al. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. J Drugs Dermatol. 2011;10:885-892.